Merck is trying to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.
In this article
Pharma giant Merck
is buying U.S. biotech firm Terns Pharmaceuticals
for $6.7 billion, the company said Wednesday.
This is the third multibillion-dollar acquisition for Merck over the past year as the company looks to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.
Terns Pharma stock has jumped since promising clinical data on its bone and blood cancer treatment last year
The multi-year effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster…
Merck said on Monday it will split its human-health business into two divisions, separating its cancer franchise from its…
Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, the companies said on Friday, gaining access to an…
Merck built a wall of patents that keeps a cancer drug's price – and its profits – high. Hospitals often add to the cost for…
Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.
